Up 13% in a day, is this FTSE 250 stock set for a comeback?

Shares in FTSE 250 footwear company Dr Martens jumped 13% on Thursday. But is an 18% revenue decline really something to get excited about?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Operational mistakes and a tough macroeconomic environment have made Dr Martens (LSE:DOCS) one of the worst FTSE 250 shares to own recently. But that might be changing.

Created with Highcharts 11.4.3Dr. Martens Plc PriceZoom1M3M6MYTD1Y5Y10YALL30 Nov 201930 Nov 2024Zoom ▾Jan '20Jul '20Jan '21Jul '21Jan '22Jul '22Jan '23Jul '23Jan '24Jul '242020202020212021202220222023202320242024www.fool.co.uk

The stock jumped 13% on Thursday (28 November) after an earnings report that the market took positively. So could this be the start of a strong turnaround?

What was so good?

The headline news that caused the share price to jump is that revenues were down 18%. That’s right – revenues fell by almost a fifth and the stock is moving higher as a result.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

It’s not immediately obvious why that should be a cause for investor optimism. But the reason is that it’s actually in line with what management had been forecasting for the period. 

That’s been unusual for Dr Martens since the company went public. It’s regularly issued profit warnings and these are why the stock has been falling over the last couple of years.

Against that backdrop, things actually being no worse than expected is a relative positive. And there are other signs management’s starting to get things under control as well. 

Actual positive news

The report wasn’t just about a decline that was no worse than anticipated. There are some genuinely encouraging signs for investors, not just ones that were better than very low expectations.

These included lower inventory levels, reduced staffing costs, and an improvement in the firm’s net debt position. And management indicated there might be more to come in the near future. 

End markets are still weak, but there isn’t much Dr Martens can do to change that. What it can do however, is get itself in the best position possible to profit when things pick up.

It looks as though this is exactly what the company’s trying to do. And that’s why the stock has started climbing again despite sales continuing to fall and the firm reporting a net loss.

Recovery timeline

At the start of the year, I was optimistic about Dr Martens’ shares. I thought the business had made it through the worst and that it was just a matter of waiting for a recovery.

I might still be right about that, but the recovery hasn’t materialised yet. And investors should note the outlook from here is complicated by a couple of issues. One is the change in CEO. There’s a lot of optimism about Ije Nworkorie’s marketing abilities, but with things starting to improve, a change of leadership represents something of a risk.

Another is the potential threat of tariffs in the US. This is the company’s largest market and the effect of higher prices might delay the anticipated recovery even further.

Time to buy?

I sold my Dr Martens shares in April. Rumours of a potential takeover caused the stock to reach 92p and I figured it would need a pretty optimistic view of a recovery to justify that price. 

Even after this week’s bounce, the share price is still well short of where I sold it. So I think I can afford to wait a bit longer and see how things take shape before considering buying again.

Should you invest £1,000 in BP right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if BP made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Up 30% in weeks, does the BAE Systems share price still offer value?

The BAE Systems share price has been on a tear over the past couple of months. This writer sees limited…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Hunting for shares to buy as the market trembles? Remember this!

After a choppy week in global stock markets, our writer goes back to basics in his hunt for bargain shares…

Read more »

Investing Articles

3 simple principles to help build wealth in an ISA

As a new tax year opens up new ISA allowances for many investors, our writer shares a trio of things…

Read more »

Investing Articles

US trade tariffs: what they could mean for UK shares like Ashtead, Compass Group, and Experian

US trade tariffs continue to rock global markets, and the UK is no exception. Our writer considers how a new…

Read more »

Mindful young woman breathing out with closed eyes, calming down in stressful situation, working on computer in modern kitchen.
Dividend Shares

The Trump slump has smashed these FTSE 100 shares!

After a rough week for US and UK shares, investors have been shaken. But now these FTSE 100 stocks have…

Read more »

Investing Articles

£10,000 invested in Rolls-Royce shares 5 years ago is now worth…

Rolls-Royce shares have been on fire since April 2020. Part of this is the result of pandemic restrictions lifting, but…

Read more »

Young Asian woman with head in hands at her desk
Investing Articles

£10,000 invested in Tesla stock at its peak in 2024 is now worth…

Over the last few months, Tesla stock has lost nearly half its value. Here, Edward Sheldon explores a few takeaways…

Read more »

Investing Articles

Is the S&P 500 heading for an epic stock market crash?

Our writer shares his thoughts on a very crazy time for the S&P 500 and the wider stock market. How…

Read more »